Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Apr 19;92(9):1684–1689. doi: 10.1038/sj.bjc.6602564

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2005 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Body weight change relative to pretreatment value (mean±s.e.m.) in healthy B6D2F₁ mice receiving gemcitabine (↓) on days 1, 4, 7 and 10 at one of six circadian times. Circadian times are expressed in hours after light onset (HALO). (A) Body weight change as a function of gemcitabine timing over 2 weeks following treatment onset at one of three dose levels (120, 160 or 200 mg kg⁻¹ inj⁻¹) (P from two-way ANOVA<0.001 for effects of dose and circadian time). (B) Body weight change at nadir as a function of dose and dosing time.